linjc16/ctgov huggingface dataset:
Pain Types and Pain Severity in Chronic Low Back Pain

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to characterize the distribution of pain phenotypes in people with chronic low back pain and to determine the effects of pain phenotypes on pain severity, functional status and quality of life. Participants will be examined to determine the type of pain and questions will be asked to identify the effects.

Official Title
-----------------
The Effects of Pain Types on Pain Severity and Quality of Life in Chronic Low Back Pain

Conditions
-----------------
Chronic Low-back Pain

Intervention / Treatment
-----------------
* Diagnostic Test: Visual Analogue Scale


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: having chronic low back pain be over 18 years old Exclusion Criteria: Those under the age of 18 Those with major psychiatric illness, Those with communication problems

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Visual Analogue Scale|Clinical criteria and rating system for nociplastic pain affecting the musculoskeletal system and PainDETECT scale to determine pain type SF-36 Quality of Life Scale, Roland Morris Disability Questionnaire, Pain Catastrophizing Scale, and Visual Analog Scale to determine the effects|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| identification of pain types(determination of nociceptive, neuropathic, nociplastic pain rates) | Neuropathic pain with PainDETECT scale, Clinical criteria and rating system for nociplastic pain affecting the musculoskeletal system nosplastic pain will be evaluated | 01.03.2023 | 
| Pain levels of those with nociplastic, neuropathic and nociceptive pain | Pain severity with Visual Analogue Scale,(0-10)higher scores indicate more pain | 01.03.2023 | 
| pain effect | quality of life with SF-36, | 01.03.2023 | 
| disability, | disability with Roland Morris Disability Questionnaire, | 01.03.2023 | 
| patient's feelings, thoughts, and feelings about pain and disaster. | The Pain Catastrophizing Scale is used to assess the patient's feelings, thoughts, and feelings about pain and disaster. | 01.03.2023 |
Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to treat advanced or recurrent endometrial cancer, paclitaxel-containing regimen is the preferred chemotherapeutic regimen which is selected by most physicians. Docetaxel may have similar efficacy and more favorable treatment related toxicity profile as tested in epithelial ovarian cancer trials. Therefore, the investigators aimed to evaluate the efficacy and safety of docetaxel plus cisplatin in patients with advanced or recurrent endometrial cancer.

Official Title
-----------------
A Phase II Trial of Docetaxel / Cisplatin in Patients With Recurrent or Stage IVb Endometrial Cancer

Conditions
-----------------
Advanced or Recurrent Endometrial Cancer

Intervention / Treatment
-----------------
* Drug: Doctaxel
* Drug: Cisplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed chemotherapy naïve endometrial cancer One of following histology Endometrioid, UPSC, CCCa, squamous, adenosquamous, mixed FIGO stage IVb or recurrent endometrial cancer (incurable by surgery and/or RT) At least one measurable lesion by RECIST on CT ECOG PS: 0-2 Age: 20-75 Adequate organ function BM: ANC≥1,000/mm3, Plt≥100X103/mm3 Kidney: Creatinine<1.25 × UNL이고, GFR ≥ 60 Liver: AST, ALT< 3×UNL, T- bil<1.5 mg/ mm3 Informed Consent Contraception during study period Exclusion Criteria: Previous chemotherapy RT, hormone therapy, or immunotherapy within 1 month Other malignant disease Uncontrolled medical disease Infection requiring antibiotics Symptomatic CHF, RF, Angina, Arrhythmia, etc. Neurosis or psychosis Pregnancy, breast-feeding Etc.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Chemotherapy<br>Docetaxel 70mg/m2BSA + Cisplatin 60mg/m2BSA, q 3 weeks, 8cycles | Drug: Doctaxel<br>* Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles<br>Drug: Cisplatin<br>* Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate |  | 3 months after completion of study treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival |  | 2 years after completion of study treatment | 
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability |  | Before each chemotherapy, an expected average of 3 weeks | 
| Quality of life |  | 3 months after completion of study treatment |
Quality of Chest Compressions After a Night Shift

Study Overview
=================
Brief Summary
-----------------
The investigators sought to evaluate the influence of fatigue after a night shift on the quality of Chest Compressions (CC) in CardioPulmonary Resuscitation (CPR), among physicians.

Detailed Description
-----------------
This is a non inferiority cluster randomized trial on three Emergency Departments (ED) and five Intensive Care Unit (ICU) from three urban academic hospital in Paris, France. The investigators evaluated the quality of CC with a low-fidelity manikin and its electronic feedback device. The investigators tested subjects on a 6-minutes CC-only CPR scenario, including 2 minutes of pause. Physicians were tested either on a control day then after a night shift, or after a night shift then on a control day.

Official Title
-----------------
Weaker Chest Compression After Nightshift : The We CAN Study.

Conditions
-----------------
Cardiac Arrest

Intervention / Treatment
-----------------
* Other: CPR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Resident / Physicians in emergency departement (ED) or taking night in ED Resident / Physicians in Intensive Care Unit (ICU) or taking night in ED Nightshift > 18 hours Exclusion Criteria: Stop chest compressions before 2 minutes
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Control<br>The investigators measure quality of chest compressions before nightshift. Control group | Other: CPR<br>* Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes<br>|
| Other: OFF<br>The investigators measure quality of chest compressions before nightshift. After night shift group | Other: CPR<br>* Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the proportion of CC with a depth higher than 50mm | The investigators evaluated the quality of CC with a low-fidelity manikin and its electronic feedback device. | 2 minutes of chest compressions | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of chest compressions | The investigators evaluated the quality of CC with a low-fidelity manikin and its electronic feedback device. | 2 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fatigue, motor skills, cardiopulmonary resuscitation
Hemodynamic Change of Coronary Atherosclerotic Plaque After Evolocumab Treatment

Study Overview
=================
Brief Summary
-----------------
Compelling evidences indicate that lipid-lowering therapy can reduce the high-risk plaque feathers and improve the coronary flow reserve. This study is going to investigate the change of lesion-specific hemodynamic significance as determined by ML(Machine Learning)-based CT-FFR (Computed Tomography-Fractional Flow Reserve)after Evolocumab treatment.

Official Title
-----------------
Hemodynamic Change of Coronary Atherosclerotic Plaque After Evolocumab Treatment: A Serial Follow-Up Study by Computed Tomography-Derived Fractional Flow Reserve

Conditions
-----------------
Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1.baseline CCTA revealed at least one lesion with stenotic extent from 50% to 69% on major epicardial arteries (diameter ≧2 mm); 2.patients were referred for optimal medical treatment; 3.patients agreed to undergo follow-up CCTA at 1-year interval. Exclusion Criteria: 1.patients had previous history of myocardial infarction or coronary revascularization; 2.patients were contraindicated to the usage of iodine contrast media; 3.image quality of baseline or follow-up CCTA was severely impaired (in presence of severe artifact, non-diagnostic); 4.patients withdrew the informed consents during follow-up; 5.patients experienced major adverse cardiac events during follow-up; 6.patients refused to undergo follow-up CCTA; 7.lost follow-up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Enrolled Cohort<br>200 selected patients will be recruited, who have diagnosed with coronary atherosclerosis disease(stenotic extent from 50% to 69% on major epicardial arteries) by coronary computed tomography angiography(CCTA). Every two weeks, these patients will be treated with Elococumab Injection (1ml:140mg),ih.This therapy will last for one year. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the change of lesion-specific CT-FFR | After one year's treatment of Elovocumab Injection, the patients will undergo follow-up CCTA again. We will measure the proximal and distal CT-FFR for each lesion.At the same time ,we will calculated the change in CT-FFR value across the lesion(ΔCT-FFR=CT-FFRproximal-CT-FFRdistal).To compare the parameters above,we shall identify whether the treatment of Elovocumab Injection improves the lesion-specific CT-FFR. | June 2020 to December 2021 |
National Survey on Hypertension in Cardiologic Private Practice

Study Overview
=================
Brief Summary
-----------------
To evaluate (with sufficient accuracy) the profile(demographic and clinical characteristics, health care management) of hypertensive patients seen in private cardiology consultation by holding account of type of exercise of the cardiologist (private exclusive or mixed hospital and private).

Official Title
-----------------
Profile of Hypertensive Patients Seen in Private Cardiology Consultation

Conditions
-----------------
Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male or female > or = 18 years old Known hypertension agree to take part in this study Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographic, clinical and health care characteristics |  | Once | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, Private cardiology consultation, Patients with hypertension
Assessment of Right Ventricular 2d-strain in Acute Respiratory Distress Syndrome

Study Overview
=================
Brief Summary
-----------------
Assessment of right ventricular (RV) function in patients with acute respiratory syndrome (ARDS) is warranted because RV failure is frequent and associated with worse outcome. Transthoracic echocardiography is the cornerstone of RV assessment but it remains challenging. Quantification of RV deformation by speckle-tracking imaging echocardiography (STE) is a widely available and reproducible technique that readily provides an integrated analysis of all segments of the RV. This study aims to investigate the accuracy of STE-derived strain parameters in assessing RV function during ARDS.

Official Title
-----------------
ARDStrain : Assessment of Right Ventricular 2d-strain in Acute Respiratory Distress Syndrome

Conditions
-----------------
ARDS

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with moderate or severe ARDS (Berlin definition) receiving mechanical ventilation (>48h estimated length) Transthoracic echocardiography performed during the first 36h after ICU admission Exclusion Criteria: pregnancy protected or deprived of Liberty major chronic respiratory disease history of clinical right heart failure chronic heart failure with LVEF < 35% severe valvular heart disease under 18 or protected-adults

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure of longitudinal peak systolic strain |  | up to 36 hours after Intensive Care Unit admission | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure of PaO2/FiO2 ratio |  | up to 36 hours after Intensive Care Unit admission | 
| Ventilator-free days |  | 28 days | 
| Mortality |  | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
echocardiography
Optimal EGM Configuration for Morphology Discrimination

Study Overview
=================
Brief Summary
-----------------
The study will be a prospective cohort study of 20 patients recruited from site's Defibrillator Clinic patient population who are followed at the site. Hypothesis: Among the available EGM configuration options, one is better than the others for detection enhancements purposes.

Official Title
-----------------
Optimal EGM Configuration for Morphology Discrimination

Conditions
-----------------
Premature Ventricular Complexes

Intervention / Treatment
-----------------
* Other: Pacing interventions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must already have an implanted St. Jude Medical dual chamber ICD with a dual coil defibrillator lead. Patients must be willing to sign an informed consent form. Patients must have frequent PVCs (minimum of 30/hour) Exclusion Criteria: Known history of slow VT (under 160 bpm). Patients under the age of 18 years. Pregnant women. Pacemaker dependent rhythm. Ongoing angina pectoris. Current NYHA Class 3-4 heart failure.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ICD patient with frequent PVCs<br> | Other: Pacing interventions<br>* 10 seconds recording of atrial paced rhythm at 100 ppm in sitting 10 seconds recording of atrial paced rhythm at 150 ppm in supine 10 seconds recording of atrial paced rhythm at 150 ppm in sitting<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| % morphology match | off line analysis | acute | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ICD patients with PVCs and EGM recordings
Efficacy and Safety of NVP-1203 in Patients With Acute Low Back Pain

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety NVP-1203 in patients with Acute low back pain

Detailed Description
-----------------
This study is a randomized, double-blind, active- and placebo-controlled, parallel, phase II study to evaluate efficacy and safety of NVP-1203 in patients with Acute low back pain

Official Title
-----------------
A Randomized, Double-blind, Active- and Placebo-controlled, Parallel, Multicenter, Phase II an Exploratory Clinical Trial to Evaluate the Efficacy and Safety NVP-1203 in Patients With Acute Low Back Pain

Conditions
-----------------
Acute Low Back Pain

Intervention / Treatment
-----------------
* Drug: NVP-1203
* Drug: NVP-1203-R
* Drug: NVP-1203 placebo
* Drug: NVP-1203-R placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who have ability to comprehend the contents of study and before participating in trial and have willingness to sign of informed consent in writing 19 Years and older A patient has symptom of acute low back pain Exclusion Criteria: Subjects who cannot prohibit anti-inflammatory drug or muscle relaxants during clinical trial Inadequate subject for the clinical trial by the investigator's decision

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NVP-1203<br>NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose | Drug: NVP-1203<br>* oral dose for 7 days<br>Drug: NVP-1203-R placebo<br>* oral dose for 7 days<br>|
| Active Comparator: NVP-1203-R<br>NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose | Drug: NVP-1203-R<br>* oral dose for 7 days<br>Drug: NVP-1203 placebo<br>* oral dose for 7 days<br>|
| Placebo Comparator: Placebo<br>NVP-1203 placebo plus NVP-1203-R placebo for up to 7 days, oral dose | Drug: NVP-1203 placebo<br>* oral dose for 7 days<br>Drug: NVP-1203-R placebo<br>* oral dose for 7 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS Pain Intensity | Improvement in VAS compared to baseline | 3, 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Finger to Floor Distance (FFD) | Improvement in FFD compared to baseline | 3, 7 days | 
| Oswestry Disability Index(ODI) | Improvement in ODI compared to baseline | 3, 7 days | 
| Investigator Global Assessment of Response to Therapy(IGART) | Improvement in IGART compared to baseline | 7 days |
Navigator 1.5 Accuracy Study

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to confirm that the accuracy and safety of Version 1.5 of the FreeStyle Navigator Continuous Glucose Monitoring System are not impacted by the updates to the system algorithm and minor changes to the user interface and sensor delivery unit, such as adhesive sterilization method. It is anticipated that information collected will be submitted as a supplement to Premarket Approval Application (P050020) to the US Food and Drug Administration for approval to market this version of the system.

Official Title
-----------------
In Clinic Evaluation of the FreeStyle Navigator® Continuous Glucose Monitoring System Version 1.5

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Device: FreeStyle Navigator Continuous Glucose Monitoring System Version 1.5


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History consistent with Type 1 diabetes for at least 2 years prior to enrollment; For at least 6 months prior to enrollment, insulin pump user or multiple daily insulin injections; At least 18 years of age; Available and capable of following the protocol instructions provided by the healthcare professional; Signed and dated Informed Consent form. Exclusion Criteria: Pregnancy; Type 2, gestational, or secondary diabetes; Known allergy to medical grade adhesives or skin disinfectant; Skin abnormalities at the insertion sites that would confound the assessment of the effect of the device on the skin; Blood donation within 6 weeks prior to beginning study activities; Within past 6 months, severe hypoglycemic episode(s) resulting in hospitalization or loss of consciousness; Active myocardial ischemia; Previous history of stroke; Any other concomitant medical condition that in the opinion of the principal investigator would likely affect the evaluation of device performance and/or safety; Current participation in another clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetes<br>Patients with type 1 diabetes requiring multiple daily insulin injections or using insulin pumps | Device: FreeStyle Navigator Continuous Glucose Monitoring System Version 1.5<br>* This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Continuous Glucose Monitoring, Accuracy, Continuous Glucose Error-Grid Analysis